Product name:CIPROFLOXACIN 500 MG CAPSULE
Company name:
DIN:02234289
Status:Marketed
Status date:2025-03-16
| Active ingredient(s) | Strength |
|---|---|
| CIPROFLOXACIN | 500 MG |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
Ciprofloxacin is a fluoroquinolone antimicrobial drug which is used to treat various bacterial infections and infections caused by susceptible organisms. It is commonly prescribed for infections of the urinary tract, skin, and reproductive system. However, it has a relatively long half-life of approximately 30–35 hours, making it a highly desirable drug for research purposes. Ciprofloxacin is a white crystalline powder with a solubility of 0.2–1.0 mg/mL. It has been demonstrated that it can be easily dispersed in aqueous solution and administered directly to the human body, making it a convenient and efficient solution for the administration of antibiotics to various organisms.
Ciprofloxacin is widely used for the treatment of several bacterial infections, including urinary tract infections, respiratory tract infections, skin and skin-wound infections, urinary tract infections associated with sexually transmitted diseases (STDs), and bacterial urinary tract infections (UTI). It has also been shown to be effective in treating infections of the skin, soft tissue, bone, and soft tissues, as well as infections of the blood, respiratory, urinary tract, bone, and skin.
The use of Ciprofloxacin has been extensively studied in animal models of human infections, including infections of the urinary tract, skin, skin-wound, bone, and skin-associated tissues. It has also been demonstrated that it can effectively treat bacterial infections in vivo, including in animals, as well as in vitro, in vitro, and in vivo. Furthermore, it has been demonstrated that it can effectively treat STDs, such as chlamydia, gonorrhea, syphilis, and certain types of bacterial sexually transmitted diseases (STDs) in vitro.
In recent years, the use of Ciprofloxacin has gained significant attention in clinical research and in the medical community. A few studies have investigated the use of Ciprofloxacin in humans in vitro, including its potential impact on sperm quality and the use of Ciprofloxacin in men with impaired sperm motility and poor sperm motility.
In vitro fertilization (IVF) has shown promising results in terms of sperm quality, motility, and morphology. In vitro fertilization has shown promise in terms of sperm motility, morphology, and quality, in addition to the potential of increasing sperm count. IVF is one of the most advanced and expensive technologies in the pharmaceutical industry, and it can be performed at home without being affected by the requirement for hospital or hospitalization.
Ciprofloxacin is also being used in research to evaluate the impact of its potential in vitro activity on fertility and to understand the role of sperm in fertility in men.
The Ethics Committee of the Institute of Biology and Biotechnology (Iblynn), College of Pharmacy, University of New South Wales, Australia, approved this study and informed consent was obtained from all patients included in the study. The study protocol was approved by the Ethics Committee of the Institute of Biology and Biotechnology, College of Pharmacy, University of New South Wales, Australia. The study was performed according to the principles of the Declaration of Helsinki and Good Clinical Practice. The Institutional Review Board of the Institute of Biology, College of Pharmacy, University of New South Wales approved the study. The Institutional Review Board of the Institute of Biology, College of Pharmacy, University of New South Wales approved the study protocol.
All patients included in the study were female, aged between 19 and 65 years, diagnosed with a bacterial infection, with a mean infection duration of 14 days, and with a mean cumulative infectious disease (CID) severity of 4.5–5.0. We included in this study, patients with a mean cumulative infectious disease (CID) of less than 3 days, and patients with a cumulative infectious disease (CID) of more than 4 days. The duration of infertility ranged from 5 days to 24 months, with a mean duration of 3.1 months. The study was conducted between January and March 2014. The study was approved by the Institutional Review Board of the Institute of Biology and Biotechnology, College of Pharmacy, University of New South Wales, Australia.
Ciprofloxacin is a broad-spectrum antibiotic belonging to the fluoroquinolone family. It is commonly used in the treatment of various bacterial infections, particularly those associated with urinary tract infections, respiratory tract infections, and gastrointestinal infections. It is commonly used to treat severe bacterial infections such as bacterial vaginosis, especially those that cause in the stomach, duodenum, or oesophagus ().
Ciprofloxacin is commonly used to treat a variety of bacterial infections, including urinary tract infections, intra-abdominal infections, intra-abdominal infections of the oesophagus, typhoid fever, and acne (). The mechanism of action of ciprofloxacin involves binding to bacterial ribosomes, interfering with the activity of bacterial protein synthesis (). Furthermore, ciprofloxacin has anti-inflammatory properties and can effectively reduce swelling in the body, thereby alleviating pain and inflammation associated with various conditions, such as arthritis and osteoarthritis ().
Ciprofloxacin has several applications in the treatment and management of various bacterial infections, including urinary tract infections (UTIs), intra-abdominal infections (IBIs), typhoid fever, and gastrointestinal infections. Here, we review the pharmacological properties and clinical applications of ciprofloxacin.
Ciprofloxacin has several applications in the treatment and management of various bacterial infections. Among these, UTIs, IBIs, and typhoid fever are the most common causes of IBIs (). Additionally, ciprofloxacin has a broad spectrum of activity against gram-negative and some gram-positive bacteria, includingKlebsiellaspp.,Pseudomonasspp., andStaphylococcusspp. (; ).
UTIs are a leading cause of IBIs among women, accounting for approximately 80% of all IBIs in the United States. UTIs account for approximately 80% of all IBIs in the United States (). However, IBIs account for less than 5% of all IBIs in women (). In addition, IBIs are associated with more severe infections, such as uncomplicated gonorrhea, chlamydia, and human immunodeficiency virus (HIV) infection (; ; ; ; ).
The prevalence of IBIs among women in the United States is increasing, especially among Black women and younger women. The incidence of IBIs among Black women is higher than that of white women and the incidence of IBIs among Black women is also increasing, which may be due to increasing societal discrimination, higher socioeconomic status, and heightened risk of infection (; ).
In addition to the above-mentioned factors, ciprofloxacin has been associated with several other adverse outcomes, including gastrointestinal infections, including IBIs, UTIs, and typhoid fever (). The risk of these adverse outcomes increases with age, with a higher prevalence of IBIs among Black women in this age group compared to white women (), and with an increased incidence of IBIs among Black women among younger and older women (; ; ; ).
Ciprofloxacin is classified as a fluoroquinolone, meaning that it is available in tablet form. Fluoroquinolones are commonly prescribed for various bacterial infections, including UTIs, IBIs, and typhoid fever (; ; ; ; ). However, ciprofloxacin is not specifically designed to treat UTIs and does not directly target IBIs. In addition, ciprofloxacin is not approved for use in treating IBIs in women, as it has a broader spectrum of activity against gram-negative and some gram-positive bacteria (; ).
The efficacy of ciprofloxacin in treating various bacterial infections has been evaluated in numerous studies, with few studies evaluating its safety and efficacy in patients with IBIs (). For example, in a clinical trial involving 149 patients with IBIs, fluoroquinolone treatment was associated with a significant reduction in the incidence of UTI, IBIs, and IBIs (; ; ; ). Furthermore, a single-arm placebo-controlled trial in a community-dwelling black women demonstrated that ciprofloxacin treatment did not significantly improve the incidence of UTI or IBIs (; ; ; ).
The following is the list of brand names that have the same active ingredient as Ciprofloxacin, and the difference of brand names is the difference in the active ingredient.
1. Fluoroquinolone antibiotics (Cipro) are used to treat various infections caused by bacteria and protozoa. The active ingredient in Ciprofloxacin, fluoroquinolone antibiotics, is ciprofloxacin. Ciprofloxacin is also used to treat infections of the eye, ear, urinary tract, skin, and nasal passages, such as ear infections, pneumonia, sinusitis, and urinary tract infections.
2. Ciprofloxacin and fluoroquinolone antibiotics, in combination with other medications, may be used to treat infections caused by various bacteria and protozoa. The combination is used to treat an infection called a gram-positive, gram-negative, or gram-negative bacillary infection.
3. Ciprofloxacin is an antibiotic that kills anaerobes and parasites and increases their ability to reproduce. Ciprofloxacin is used to treat infections caused by certain bacteria and protozoa. The drug is also used to treat gonorrhea and syphilis.
4. Ciprofloxacin may be used to treat a number of different conditions including ear infections, pneumonia, urinary tract infections, infections caused by certain bacteria, and infections caused by certain protozoa.
5. Ciprofloxacin may be used to treat various conditions such as:
Ciprofloxacin may be used to treat infections caused by certain bacteria and protozoa.
6. The drug is also used to treat an infection called a gram-positive, gram-negative, or gram-negative bacillary infection.
7.
8.
9.
10.
11.
Javascript must be enabled for the correct page display
1
Complete our online health assessment any time and request care.Please watch out for our response so we can get your treatment to you as quickly as possible.
2
If medically appropriate, a member of the Nurx medical team will write a prescription for a topical antihistamine such as Ciprofloxacin to be delivered to your doorstep
3
We’ll send the prescription back to your servicepayer-still if not our service failing at this early stage.
4
Please keep an eye on the situation and notify our medical team if you experience any side effects or develop skin rash or itching.
drains the immune system from the body and restores it to health.
The side effects listed below are not common and are not typically serious.
They can let you know if you show any unusual symptoms surprise your family doctor or GP.
Stade de France Pharmacy